BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-14.73%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.16B
AUM Growth
+$5.16B
(-18%)
Cap. Flow
-$29M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
231
New
16
Increased
80
Reduced
52
Closed
17
Top Buys
| 1 |
Black Diamond Therapeutics
BDTX
|
$33.2M |
| 2 |
Fate Therapeutics
FATE
|
$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
$21.8M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$21.5M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$21M |
Top Sells
| 1 |
Teladoc Health
TDOC
|
$85.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
$49.3M |
| 3 |
Moderna
MRNA
|
$29.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$27.6M |
| 5 |
QuidelOrtho
QDEL
|
$21.9M |
Sector Composition
| 1 | Healthcare | 95.76% |
| 2 | Technology | 0.56% |
| 3 | Industrials | 0.54% |
| 4 | Communication Services | 0.17% |
| 5 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $396M | 7.68% |
8,379,642
-52,178
| -0.6% | -$2.47M |
|
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $303M | 5.87% |
1,273,089
-116,200
| -8% | -$27.6M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $282M | 5.47% |
3,259,474
-58,900
| -2% | -$5.1M |
|
4
Incyte
INCY
$16.5B
| $243M | 4.72% |
3,324,000
-193,000
| -5% | -$14.1M |
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $193M | 3.75% |
1,775,264
-89,519
| -5% | -$9.74M |
|
6
Esperion Therapeutics
ESPR
$448M
| $159M | 3.08% |
5,037,890
+512,880
| +11% | +$16.2M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $139M | 2.69% |
3,905,444
-19,510
| -0.5% | -$692K |
|
8
Halozyme
HALO
$8.56B
| $138M | 2.67% |
7,663,956
-372,900
| -5% | -$6.71M |
|
9
argenx
ARGX
$43.6B
| $128M | 2.49% |
974,504
+6,515
| +0.7% | +$858K |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $120M | 2.32% |
1,331,328
-57,600
| -4% | -$5.17M |
|
|
11
Moderna
MRNA
$9.37B
| $118M | 2.29% |
3,950,181
-984,900
| -20% | -$29.5M |
|
|
12
Intuitive Surgical
ISRG
$170B
| $109M | 2.12% |
220,371
+44,095
| +25% | +$21.8M |
|
13
Abbott
ABT
$231B
| $101M | 1.97% |
1,284,272
-41,148
| -3% | -$3.25M |
|
|
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
| $90.8M | 1.76% |
6,983,385
+41,000
| +0.6% | +$533K |
|
15
Medtronic
MDT
$119B
| $85.2M | 1.65% |
945,316
+96,986
| +11% | +$8.75M |
|
16
Elevance Health
ELV
$71.8B
| $83M | 1.61% |
365,603
+40,429
| +12% | +$9.18M |
|
17
UnitedHealth
UNH
$281B
| $78.9M | 1.53% |
316,208
+40,998
| +15% | +$10.2M |
|
18
Exelixis
EXEL
$10.1B
| $68.5M | 1.33% |
3,975,400
+44,700
| +1% | +$770K |
|
|
19
Bristol-Myers Squibb
BMY
$96B
| $67.2M | 1.3% |
1,205,472
-883,770
| -42% | -$49.3M |
|
20
Humana
HUM
$36.5B
| $62.2M | 1.21% |
198,118
-29,329
| -13% | -$9.21M |
|
21
Nektar Therapeutics
NKTR
$568M
| $62.2M | 1.21% |
3,484,713
+67,715
| +2% | +$1.21M |
|
22
Cigna
CI
$80.3B
| $61.9M | 1.2% |
349,289
+30,143
| +9% | +$5.34M |
|
|
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $61.5M | 1.19% |
1,311,713
+5,400
| +0.4% | +$253K |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $57.4M | 1.11% |
3,731,819
+1,365,819
| +58% | +$21M |
|
25
Becton Dickinson
BDX
$55.3B
| $56.8M | 1.1% |
247,064
-4,948
| -2% | -$1.14M |
|